For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 10,839,150 | 10,412,150* | 7,649,697 | 5,270,967 |
| Selling, general and administrative | 7,376,123 | 6,258,228* | 5,611,503 | 5,919,731 |
| Change in fair value contingent consideration | 373,354 | 97,071.5* | 492,827 | 358,420 |
| Total costs and expenses | 17,841,919 | 16,573,306.5 | 12,768,373 | 10,832,278 |
| Loss from operations | -17,841,919 | -16,573,306.5* | -12,768,373 | -10,832,278 |
| Interest income | 1,461,079 | 1,082,822* | 838,093 | 916,755 |
| Net loss | -16,380,840 | -15,490,484.5 | -11,930,280 | -9,915,523 |
| Basic EPS | -0.1 | -0.135 | -0.13 | -0.11 |
| Diluted EPS | -0.1 | -0.135 | -0.13 | -0.11 |
| Basic Average Shares | 172,306,932 | 114,869,972 | 90,050,973 | 90,009,625 |
| Diluted Average Shares | 172,306,932 | 114,869,972 | 90,050,973 | 90,009,625 |
Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc. (IKT)